Rws Share Discussion Threads

[redartbmud] 27/8/2020 08:12

??

I take it as a negative for Rws.
Maybe it will be viewed in a different light going forward.
No future acquisitions in the pipeline for a long time.

[phillis] 07/8/2020 11:55

Some more top slicing I think

[robinnicolson] 07/8/2020 11:47

New all time high. A quality business.

[phillis] 17/7/2020 12:56

Divis today
:-)

[robinnicolson] 22/6/2020 20:51

Mail on Sunday 'Midas' update:

[robinnicolson] 13/6/2020 12:20

A good piece on RWS by Richard Beddard:

[redartbmud] 11/6/2020 13:04

Phillis

That was a good move.
I was going to do it, but procrastinated.

Hey ho....

[toffeeman] 11/6/2020 12:47

Inverse H&S??

[phillis] 11/6/2020 12:40

Top sliced a few at 657p
Time to buy back?

[shanklin] 11/6/2020 07:02

RWS tipped as a buy

[alter ego] 10/6/2020 16:04

IC recommends buying summarising as follows:

"RWS is offsetting some Covid-19 challenges with new opportunities. For example, while life sciences has seen postponed clinical trials and cancelled elective procedures, some pharmaceutical customers, including Gilead (US:GILD), are requiring greater assistance as they develop Covid-19 treatments. Meanwhile, the balance sheet looks able to weather this crisis, the dividend has been maintained and long-term demand drivers – chiefly globalisation of digital content – remain unchanged. Buy."

[shanklin] 10/6/2020 15:25

A minimal backward step due to a global pandemic. share price fall seems bizarre to me

[phillis] 09/6/2020 11:33

think this is the first time results have gone backwards

[toffeeman] 09/6/2020 11:28

Well the market doesn't see them as being significant!

[orange1] 09/6/2020 11:07

Very much so.

Iconic

Initial consideration of US$10.0m with additional deferred consideration of up to US$10.0m in RWS shares, subject to future performance.

Revenues of US$1.2m for the year ended 31 December 2019 and an adjusted EBITDA* of US$23k.

Revenues were up 100% on the previous year.

Webdunia.com

Total cash consideration of US$21.0m.

Revenues of US$13.8m for the year ended 31 March 2020 and an adjusted EBITDA* of US$3.1m.

Revenues were up 12% on the previous year and adjusted EBITDA was up by 33%.


* EBITDA - profit before tax adjusted for interest, depreciation, amortization and other non-recurring costs.

[jeffian] 09/6/2020 10:57

More acquisitions today. It is usually a feature of RWS deals that they are either immediately or shortly earnings-enhancing and I note that there is no comment this time. They appear to be 'strategic' acquisitions.

[phillis] 04/5/2020 13:47

Article in todays DT re inventors with time on their hands filing more patent applications
Good stuff

[toffeeman] 09/4/2020 13:02

Needs to reclaim 500!